Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor Receptor 2 (HER2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00015938
What this trial is testing

S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 95
Testing effectiveness (Phase 2)Study completedNCT00629616
What this trial is testing

Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 116
Not applicableStudy completedNCT04001634
What this trial is testing

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

Who this might be right for
Breast Cancer
Fudan University 285
Testing effectiveness (Phase 2)UnknownNCT03876587
What this trial is testing

Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 79
Testing effectiveness (Phase 2)Study completedNCT01827787
What this trial is testing

Eribulin in HER2 Negative Metastatic BrCa

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 83
Testing effectiveness (Phase 2)UnknownNCT04179656
What this trial is testing

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Who this might be right for
Solid TumorHER2 Gene MutationHER-2 Gene Amplification+1 more
Tianjin Medical University Second Hospital 100
Not applicableUnknownNCT03728829
What this trial is testing

Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer

Who this might be right for
ObservationalProspective
Hebei Medical University Fourth Hospital 100
Early research (Phase 1)Study completedNCT03207529
What this trial is testing

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+15 more
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT02723877
What this trial is testing

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Who this might be right for
Metastatic Breast Cancer
PIQUR Therapeutics AG 41
Testing effectiveness (Phase 2)Study completedNCT02260531
What this trial is testing

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Who this might be right for
Breast CancerBrain Tumor - Metastatic
Dana-Farber Cancer Institute 36
Not applicableUnknownNCT03979339
What this trial is testing

Feasibility of a New Technology for Isolating Circulating Tumour Cells

Who this might be right for
HER2-positive Metastatic Breast CancerOvarian CancerHormone-resistant Prostate Cancer+1 more
Centre Oscar Lambret 76
Not applicableWithdrawnNCT00898573
What this trial is testing

Lapatinib Resistance in Patients With Breast Cancer

Who this might be right for
Breast Cancer
Case Comprehensive Cancer Center
Testing effectiveness (Phase 2)UnknownNCT06308939
What this trial is testing

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 81
Large-scale testing (Phase 3)Active Not RecruitingNCT02568839
What this trial is testing

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

Who this might be right for
Early-Stage Breast CarcinomaHER-2 Positive Breast Cancer
Thomas Hatschek 202
Large-scale testing (Phase 3)Looking for participantsNCT06452277
What this trial is testing

Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer 555
Large-scale testing (Phase 3)Active Not RecruitingNCT06316531
What this trial is testing

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 274
Not applicableLooking for participantsNCT06693037
What this trial is testing

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 2,092
Not applicableLooking for participantsNCT06902545
What this trial is testing

Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04251169
What this trial is testing

Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 20
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Next Page
377